Status:
COMPLETED
Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF
Lead Sponsor:
IBSA Institut Biochimique SA
Conditions:
Infertility
Eligibility:
FEMALE
18-40 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the clinical efficacy and general tolerability of two different subcutaneous FSH preparations (Fostimon®, IBSA vs Gonal-F®, Serono Inc.) when administered to pa...
Detailed Description
This is a prospective, multicenter, investigator blinded, randomized, concurrent control, phase III clinical trial. Patients meeting the eligibility requirements of the study will be randomly assigned...
Eligibility Criteria
Inclusion
- \>/=18 and \<40 years old;
- BMI between 18 and 30 kg/m2;
- less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery);
- basal FSH \<10 IU/L and E2 \<80 pg/mL;
- Within 12 months of the beginning of the study, uterine cavity consistent with expected normal function as assessed through a hysterosalpingogram, sonohysterogram, or hysteroscopic examination;
- \>10 antral follicles 2-10 mm in size;
- Normal or clinically insignificant hematology and blood chemistry values. TSH levels must be within the normal limits for the testing laboratory, or the patient should be euthyroid as determined by the investigator (e.g. normal free thyroxine). TSH can be low secondary to exogenous thyroid medication where patient is euthyroid;
- Able and willing to sign the Patient Consent Form and adhere to the study visitation schedule.
Exclusion
- · age \<18 and \>/=40 years;
- primary ovarian failure or women known as poor responders (i.e. requiring more than 300 IU of FSH as a starting dose in previous treatment cycles or having less than 3 oocytes retrieved, or with an E2 serum concentration \<1800 pmol/L/500pg/mL);
- prior ovarian hyperstimulation syndrome (OHSS), polycystic ovarian syndrome that would normally be started at a lower FSH dose than is initially required by the study (i.e. 300 IU), or likely intolerance to even two days of 300 IU FSH.
- one or both ovaries inaccessible for oocyte retrieval;
- ovarian cysts \>20 mm;
- hydrosalpinx that have not been surgically removed or ligated;
- stage 3 or 4 endometriosis;
- oocyte donation;
- implantation of previously frozen embryos;
- patients affected by pathologies associated with any contraindication of being pregnant;
- hypersensitivity to the study medication;
- abnormal bleeding of undetermined origin;
- uncontrolled thyroid or adrenal dysfunction;
- neoplasias;
- severe impairment of renal and/or hepatic function;
- use of concomitant medications that might interfere with study evaluations (e.g. nonstudy hormonal medications, prostaglandin inhibitors, psychotropic agents).
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT00378001
Start Date
March 1 2005
End Date
May 1 2006
Last Update
February 16 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fertility Physicians of Northern California
Palo Alto, California, United States, 94301
2
San Diego Fertility Center
San Diego, California, United States, 92130
3
UCSF In Vitro Fertilization
San Francisco, California, United States, 94115-0916
4
Seattle Reproductive Medicine
Seattle, Washington, United States, 98109